Statements (291)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Im_Clone_Systems
|
| gptkbp:acquisition |
gptkb:Loxo_Oncology
gptkb:Im_Clone_Systems gptkb:Avid_Radiopharmaceuticals Loxo Oncology (2019) Prevail Therapeutics (2020) Im Clone Systems (2008) acquired Dermira acquired Loxo Oncology acquired Prevail Therapeutics |
| gptkbp:awards |
gptkb:Fortune_500
Best Places to Work Innovation Awards Top Employer Fortune 500 company Top Employer in the pharmaceutical industry |
| gptkbp:biologics |
develops biologic therapies
|
| gptkbp:business_model |
committed to research ethics
|
| gptkbp:capital |
over $200 billion
|
| gptkbp:ceo |
gptkb:David_A._Ricks
|
| gptkbp:charity |
COVID-19 relief efforts
|
| gptkbp:clinical_trial |
gptkb:Lilly_Research_Laboratories
gptkb:Type_1_diabetes Phase IV Phase II biomarker discovery Phase III Phase 3 trials Phase I diabetes management Type 2 diabetes patient-centered approach real-world evidence diabetes complications conducts numerous clinical trials over 100 ongoing Phase 1 trials Phase 2 trials diabetes medications COVID-19 treatments focus on unmet medical needs conducts all phases of clinical trials actively recruits participants conducts extensive clinical trials |
| gptkbp:collaboration |
gptkb:Duke_University
gptkb:Harvard_University gptkb:University_of_California gptkb:National_Institutes_of_Health government agencies academic institutions research organizations |
| gptkbp:collaborations |
government agencies
academic institutions biotech companies with academic institutions |
| gptkbp:community_engagement |
education initiatives
research funding disaster relief efforts health initiatives health education programs volunteer programs supports local communities |
| gptkbp:community_health |
disaster relief efforts
community health programs community engagement programs partnerships with NGOs health literacy initiatives mental health awareness campaigns sustainable health solutions collaboration with international organizations partnerships with academic institutions engages in global health initiatives collaboration with governments advocacy for health policy reforms support for chronic disease management improve access to medicines education and training for healthcare professionals HIV/ AIDS programs support for health equity research on global health challenges support for health technology innovations access to vaccines research funding for neglected diseases healthcare access in low-income countries investment in local health systems pharmaceutical donations support for diabetes care support for maternal and child health supporting vaccination efforts |
| gptkbp:conducts_research_on |
gptkb:Daniel_Skovronsky
|
| gptkbp:covid-19_antibody_treatments |
received emergency use authorization
|
| gptkbp:covid-19_impact |
developed monoclonal antibodies
|
| gptkbp:developed_by |
gptkb:Humalog
gptkb:Trulicity gptkb:Basaglar insulin products |
| gptkbp:digital_health |
telehealth initiatives
investment in digital solutions data analytics in R& D |
| gptkbp:drug_safety |
prioritizes drug safety
|
| gptkbp:employees |
over 35,000
35,000 |
| gptkbp:employs |
over 35,000 people
|
| gptkbp:fda_approvals |
receives multiple FDA approvals annually
|
| gptkbp:financial_support |
access programs
diabetes education programs affordability programs provides medication access |
| gptkbp:focus |
Pharmaceuticals
biopharmaceuticals |
| gptkbp:focuses_on |
diabetes treatment
|
| gptkbp:founded |
1876
|
| gptkbp:founder |
gptkb:Eli_Lilly
|
| gptkbp:funding |
significant investment in R& D
invests in research funding |
| gptkbp:global_presence |
over 120 countries
operations in over 120 countries operates in over 120 countries |
| gptkbp:has_a_focus_on |
gptkb:biotechnology
chronic disease management clinical research preventive care for diabetes |
| gptkbp:has_a_global_strategy_for |
diabetes treatment
|
| gptkbp:has_a_pipeline_of |
diabetes medications
|
| gptkbp:has_a_presence_in |
the diabetes market
|
| gptkbp:has_awards |
excellence in healthcare
|
| gptkbp:has_collaborations_with |
academic institutions
|
| gptkbp:has_culture |
collaborative environment
innovation-driven patient-centric |
| gptkbp:has_developed |
GLP-1 receptor agonists
|
| gptkbp:has_diversity_initiatives |
promotes workplace diversity
|
| gptkbp:has_history |
philanthropy in healthcare
innovation in diabetes therapies |
| gptkbp:has_partnerships_with |
various healthcare organizations
technology companies for diabetes management |
| gptkbp:has_received |
FDA approvals for diabetes drugs
|
| gptkbp:has_research_center |
gptkb:Lilly_Innovation_Center
multiple countries multiple locations worldwide |
| gptkbp:headquarters |
gptkb:Indianapolis,_Indiana,_USA
gptkb:USA gptkb:Indianapolis,_Indiana |
| gptkbp:healthcare |
drives healthcare innovation.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eli Lilly
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
telehealth services
digital health solutions focuses on innovative drug development diabetes technology AI in drug discovery |
| gptkbp:instruction_set |
has a robust drug pipeline
|
| gptkbp:invention |
over 10,000
holds numerous patents |
| gptkbp:investment |
pandemic preparedness
|
| gptkbp:is_a_member_of |
gptkb:Ph_RMA
|
| gptkbp:is_committed_to |
diversity and inclusion
sustainability global health initiatives healthcare innovation affordable medicines patient access improving diabetes outcomes research and development in diabetes. |
| gptkbp:is_displayed_in |
gptkb:New_York_Stock_Exchange
|
| gptkbp:is_involved_in |
clinical trials
community health initiatives global health initiatives patient education programs healthcare policy advocacy |
| gptkbp:is_known_for |
patient-centered care
research in endocrinology innovative drug development |
| gptkbp:is_recognized_for |
patient assistance programs
its contributions to diabetes research its diabetes management programs |
| gptkbp:is_vulnerable_to |
collaborated with other companies
|
| gptkbp:launched |
numerous diabetes awareness campaigns
|
| gptkbp:leadership |
diabetes care solutions
|
| gptkbp:market |
global
|
| gptkbp:market_cap |
$200 billion (2021)
over $200 billion (2021) |
| gptkbp:market_position |
oncology market
insulin market neuroscience market strong market presence in the U. S. |
| gptkbp:market_share |
diabetes medications
insulin market |
| gptkbp:marketing_strategy |
global expansion
patient access programs therapeutic area focus |
| gptkbp:number_of_employees |
over 35,000
over 38,000 |
| gptkbp:operates_in |
over 120 countries
|
| gptkbp:operating_countries |
operates in Europe and Asia
|
| gptkbp:participated_in |
healthcare conferences
|
| gptkbp:partnership |
gptkb:diabetes
gptkb:Alzheimer's_Association gptkb:Astra_Zeneca gptkb:Boehringer_Ingelheim gptkb:World_Health_Organization gptkb:Pfizer gptkb:Amgen |
| gptkbp:partnerships |
with government agencies
partners with healthcare providers |
| gptkbp:patient_education |
provides educational resources
|
| gptkbp:philanthropy |
gptkb:Lilly_Foundation
education initiatives health initiatives supports health-related charities |
| gptkbp:produces |
diabetes drugs
|
| gptkbp:products |
gptkb:diabetes
gptkb:Humalog gptkb:Trulicity gptkb:Basaglar antidepressants oncology drugs |
| gptkbp:provides_guidance_on |
diabetes management
insulin therapy diabetes treatment contributes to treatment guidelines |
| gptkbp:publications |
publishes research findings
|
| gptkbp:reach |
operates in multiple countries
|
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA for COVID-19 treatments FDA approved drugs |
| gptkbp:related_products |
gptkb:Breztri_Aerosphere
gptkb:Cymbalta gptkb:Cyramza gptkb:Emgality gptkb:Forteo gptkb:Humalog gptkb:Lilly's_COVID-19_antibody_therapy gptkb:Olumiant gptkb:Retevmo gptkb:Taltz gptkb:Trulicity gptkb:Verzenio gptkb:Zyprexa gptkb:Tremfya gptkb:Basaglar |
| gptkbp:reported_revenue_in_2022 |
$28.5 billion
|
| gptkbp:research |
gptkb:neurodegenerative_diseases
cancer treatments diabetes treatments therapeutics for infectious diseases |
| gptkbp:research_areas |
gptkb:diabetes
oncology autoimmune diseases neuroscience cardiovascular diseases immunology pain management |
| gptkbp:research_focus |
gptkb:diabetes
gptkb:Oncology oncology autoimmune diseases neuroscience immunology |
| gptkbp:revenue |
$28.5 billion (2020)
$24 billion (2020) $24.5 billion (2020) $24 billion (2022) |
| gptkbp:service_area |
Global
|
| gptkbp:small_molecules |
develops small molecule drugs
|
| gptkbp:stock_symbol |
gptkb:LLY
|
| gptkbp:subsidiaries |
gptkb:Lilly_France
gptkb:Lilly_Research_Laboratories gptkb:Lilly_USA gptkb:Lilly_Canada |
| gptkbp:subsidiary |
gptkb:Elanco_Animal_Health
|
| gptkbp:sustainability_efforts |
community engagement
environmental initiatives waste reduction diversity and inclusion programs water conservation carbon neutrality by 2030 |
| gptkbp:sustainability_initiatives |
community engagement
diversity and inclusion environmental responsibility |
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:training |
continuous professional development
provides ongoing employee training |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:uses_technology |
focus on biologics
|
| gptkbp:website |
www.lilly.com
lilly.com |
| gptkbp:bfsParent |
gptkb:biotechnology
|
| gptkbp:bfsLayer |
3
|